Ocugen Taps Rita Johnson-Greene as CFO Ahead of BLA Submissions
Ocugen named Rita Johnson-Greene as CFO, leveraging her 20-year track record in finance and operations roles at the Alliance for Regenerative Medicine, Genetix Biotherapeutics, Spark Therapeutics and AstraZeneca. She will oversee financial strategy as Ocugen prepares to submit its first of three biologics license applications this year.
1. Appointment of New CFO
On February 9, 2026, Ocugen appointed Rita Johnson-Greene as Chief Financial Officer to oversee the company’s financial operations and strategic planning during a transformative period.
2. Extensive Industry Experience
Johnson-Greene brings over 20 years of healthcare finance and operations expertise, having served as COO at the Alliance for Regenerative Medicine and VP of Sales at Genetix Biotherapeutics, where she scaled U.S. gene therapy launches, plus senior roles at Spark Therapeutics and finance positions at AstraZeneca.
3. Strategic Role in BLA Filings
She will drive Ocugen’s financial strategy as the company readies its first of three Biologics License Applications this year, supporting advancement of its modifier gene therapy platform for blindness diseases.